WO2026042870A1 - Nanoparticules lipidiques - Google Patents

Nanoparticules lipidiques

Info

Publication number
WO2026042870A1
WO2026042870A1 PCT/JP2025/029461 JP2025029461W WO2026042870A1 WO 2026042870 A1 WO2026042870 A1 WO 2026042870A1 JP 2025029461 W JP2025029461 W JP 2025029461W WO 2026042870 A1 WO2026042870 A1 WO 2026042870A1
Authority
WO
WIPO (PCT)
Prior art keywords
lipid
cells
lipid nanoparticles
nucleic acid
hacv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/JP2025/029461
Other languages
English (en)
Japanese (ja)
Inventor
隆史 小嶌
美沢 石井
薫雄 柳井
直人 犬飼
昌城 安達
秀希 峯松
彬正 妹尾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of WO2026042870A1 publication Critical patent/WO2026042870A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne : des nanoparticules lipidiques dans lesquelles un acide nucléique ayant une longueur de 10 kb ou plus et une substance cationique sont encapsulés ; une composition d'administration d'acide nucléique et un produit pharmaceutique qui contiennent les nanoparticules lipidiques susmentionnées ; et un procédé d'administration d'un acide nucléique dans une cellule, le procédé comprenant une étape de mise en contact de la composition d'administration d'acide nucléique susmentionnée avec une cellule.
PCT/JP2025/029461 2024-08-23 2025-08-22 Nanoparticules lipidiques Pending WO2026042870A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2024143393 2024-08-23
JP2024-143393 2024-08-23

Publications (1)

Publication Number Publication Date
WO2026042870A1 true WO2026042870A1 (fr) 2026-02-26

Family

ID=98865180

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2025/029461 Pending WO2026042870A1 (fr) 2024-08-23 2025-08-22 Nanoparticules lipidiques

Country Status (1)

Country Link
WO (1) WO2026042870A1 (fr)

Similar Documents

Publication Publication Date Title
JP7395483B2 (ja) ｍＲＮＡの細胞内送達のためのペプチドおよびナノ粒子
KR102544051B1 (ko) 인간화된 ttr 유전자좌를 포함하는 비인간 동물 및 사용 방법
Boado Blood–brain barrier transport of non-viral gene and RNAi therapeutics
US20230044994A1 (en) Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding Agent
EP1471944B1 (fr) Composition pharmaceutique ameliorant le transfert de gene in vivo
JP2025524469A (ja) 標的を定めた遺伝子抑制を介して低密度リポタンパク質を低減するための組成物、系、及び方法
JP2017500865A (ja) レプチンｍＲＮＡの組成物および製剤
Chen et al. A TRAIL-delivered lipoprotein-bioinspired nanovector engineering stem cell-based platform for inhibition of lung metastasis of melanoma
KR20210027389A (ko) 공여자 폴리뉴클레오티드의 삽입에 의한 게놈 편집을 위한 조성물 및 방법
KR20220070433A (ko) Stat6을 표적으로 하는 세포외 소포-aso 작제물
CN114641570A (zh) 具有靶向kras的反义寡核苷酸的细胞外囊泡
TW202444910A (zh) 編碼casx之信使rna
Huang et al. Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles
US12473568B2 (en) Non-immunogenic circular, non-viral DNA vectors
Kiselev et al. Suppression of nonsense mutations in the Dystrophin gene by a suppressor tRNA gene
WO2026042870A1 (fr) Nanoparticules lipidiques
CN112852881B (zh) 利用细胞穿膜肽增强腺相关病毒在中枢神经系统转导效率的方法
WO2024156871A1 (fr) Mélanges de nanoparticules lipidiques et de peptides pénétrant dans les cellules
US12091677B2 (en) Carboxylated nanodiamond-mediated CRISPR-CAS9 delivery system
CN117157093A (zh) 细胞外囊泡-nlrp3拮抗剂
Appelbaum et al. Impact of PEGylation and hyaluronan functionalization on lipoplex-mediated mRNA delivery to the canine retina
JP2023512732A (ja) 組換え核酸コンストラクトおよびその使用法
WO2025244134A1 (fr) Procédé pour administrer une charge utile à des cellules, et composition lipidique
EP4238581A1 (fr) Administration ciblée d'oligonucléotides dans des cellules eucaryotes à l'aide de polyplexes hybrides maltose/cyclodextrine
RU2784927C1 (ru) Отличные от человека животные, включающие в себя гуманизированный ttr локус, и способы применения

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25857076

Country of ref document: EP

Kind code of ref document: A1